Skip to Content

Label Changes for:

Dyazide (hydrochlorothiazide/triamterene) capsules

February 2010

Changes have been made to the ADVERSE REACTIONS sections of the safety label.

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – February 2010


Hydrochlorothiazide, Skin 
  • Erythema multiforme including Steven-Johnson syndrome, exfoliative dermatitis, including toxic epidermal necrolysis